Reconstitution of human PDAC using primary cells reveals oncogenic transcriptomic features at tumor onset

Xu, Yi; Nipper, Michael H.; Dominguez, Angel A.; Ye, Zhenqing; Akanuma, Naoki; Lopez, Kevin; Deng, Janice J.; Arenas, Destiny; Sanchez, Ava; Sharkey, Francis E.; Court, Colin M.; Singhi, Aatur D.; Wang, Huamin; Fernandez-Zapico, Martin E.; Sun, Lu-Zhe; Zheng, Siyuan; Chen, Yidong; Liu, Jun; Wang, Pei

doi:10.1038/s41467-024-45097-2

Download PDF

Article
Open access
Published: 27 January 2024

Reconstitution of human PDAC using primary cells reveals oncogenic transcriptomic features at tumor onset

Nature Communications volume 15, Article number: 818 (2024) Cite this article

3612 Accesses
6 Altmetric
Metrics details

Subjects

Abstract

Animal studies have demonstrated the ability of pancreatic acinar cells to transform into pancreatic ductal adenocarcinoma (PDAC). However, the tumorigenic potential of human pancreatic acinar cells remains under debate. To address this gap in knowledge, we expand sorted human acinar cells as 3D organoids and genetically modify them through introduction of common PDAC mutations. The acinar organoids undergo dramatic transcriptional alterations but maintain a recognizable DNA methylation signature. The transcriptomes of acinar organoids are similar to those of disease-specific cell populations. Oncogenic KRAS alone do not transform acinar organoids. However, acinar organoids can form PDAC in vivo after acquiring the four most common driver mutations of this disease. Similarly, sorted ductal cells carrying these genetic mutations can also form PDAC, thus experimentally proving that PDACs can originate from both human acinar and ductal cells. RNA-seq analysis reveal the transcriptional shift from normal acinar cells towards PDACs with enhanced proliferation, metabolic rewiring, down-regulation of MHC molecules, and alterations in the coagulation and complement cascade. By comparing PDAC-like cells with normal pancreas and PDAC samples, we identify a group of genes with elevated expression during early transformation which represent potential early diagnostic biomarkers.

A single-cell atlas enables mapping of homeostatic cellular shifts in the adult human breast

Article Open access 28 March 2024

A spatiotemporal atlas of cholestatic injury and repair in mice

Article 16 April 2024

High-content CRISPR screening

Article 10 February 2022

Introduction

Pancreatic ducal adenocarcinoma (PDAC) is the most common histological subtype of pancreatic cancer. This malignancy is one of the deadliest human cancers and is predicted to be the second leading cause of cancer-associated death by 2040¹. Lack of effective treatments for late stage PDAC is one of the reasons for its dismal survival rate, but major challenges also include late diagnosis, resistance to chemotherapy, and metastasis². Prevention and early diagnosis represent the most promising strategies for improving outcomes of this disease. A better understanding of the mechanisms of early PDAC tumorigenesis is the first step towards this goal. However, our current knowledge about early PDAC progression in human cells is still very limited, with some fundamental questions remaining unclear, including what the cellular origin of PDAC is and how the normal exocrine cells transform to malignant cells during PDAC initiation in response to environmental cues and oncogenic events.

More than 90% of the pancreatic mass is exocrine tissue comprised of acini that secrete large amounts of digestive enzymes and ducts that deliver the acinar secretions to the duodenum³. The duct-like histological morphology of PDACs led to the belief that human PDAC was originated from ductal cells⁴. Although multiple mouse PDAC models have been developed in the past two decades⁵, modeling human PDAC tumorigenesis remains challenging, as current human pancreatic organoids are mainly derived from human PDAC patients with advanced disease^6,7. In addition, animal studies have demonstrated that both acinar and ductal cells can serve as the cellular origin for mouse PDAC and that cell-of-origin influences the molecular subtypes and aggressiveness of PDACs^{8,9,10,11,12,13}. However, the cell-of-origin in human PDAC has yet to be proven.

In the present study, we established long-term culture systems for primary human pancreatic acinar and ductal cells followed by genetic engineering to reconstruct early human PDAC development. Our results provide direct evidence for both acinar and ductal origin of human PDAC formation, and reveal the effects of classical PDAC driver mutations on transcriptional reprogramming in human cellular context. In addition, we identified a group of genes upregulated during the transition stage from normal exocrine cells to early PDAC. These genes were also highly expressed in TCGA PDAC data compared with normal pancreas data, suggesting their possible participation in human pancreatic tumorigenesis as well as their potential as early diagnostic biomarkers.

Results

Long-term 3D acinar cells culture mimics in vivo injuries-induced metaplasia

Disease-free islet-depleted pancreatic acinar fractions were obtained from human organ donors (Supplementary Data 1) and stained for known acinar marker AMY2 and ductal marker KRT19, which revealed the presence of both acinar and ductal lineages (Fig. 1a). Flow cytometry was then used to sort the two lineages. Sorted acinar cells (UEA-1^highCLA^-)¹⁴ showed distinct secretory zymogen granules and rough endoplasmic reticulum structures by electron microscopy (EM), confirming acinar identity (Fig. 1a). Sorted ductal cells (UEA-1^lowCLA⁺) showed ductal-associated cilia structures.

**Fig. 1: Primary human 3D acinar culture associated with metaplastic features.**

RNA-seq analysis of sorted cells from 5 independent donors revealed differential expression of 2087 acinar-high genes and 1906 ductal-high genes, including 273 differentially expressed transcriptional factors (TFs) (Fig. S1a, b, fold-change > 2; adj.p < 0.05). As expected, the most highly expressed genes in the acinar population included many digestion enzymes (Fig. S1c). The top enriched gene ontology (GO) terms in acinar-high genes included cytoplasmic translation, ribosome assembly, digestion, and protein secretion, corroborating normal acinar function (Fig. 1b). In comparison, ductal cells expressed high levels of tubule morphogenesis-associated genes and several signaling pathways including WNT pathway and transforming growth factor beta pathway.

To establish an acinar and ductal culture model, we cultured sorted cells separately in a WNT-dependent 3D organoid system⁷. Interestingly, the ductal-derived organoids initially proliferated rapidly, but ceased to proliferate within 4 passages (Fig. 1c). On the other hand, the acinar-derived organoids proliferated at a much slower pace during early passages, then started to expand rapidly and could be continually passaged for more than 6 months and cryopreserved. The cultured acinar organoids showed a typical ring-like morphology and expression of MUC5AC, a marker for KRAS induced acinar metaplasia (Fig. S1d).

The transcriptomic profiles of acinar-derived organoids (in vitro culture for at least 6 weeks) established from 6 independent donors appeared to be distinct from both fresh acinar and fresh ductal cells (Fig. S1e). A comprehensive three-group comparison of the fresh acinar, fresh ductal, and cultured acinar organoid expression data identified >10,000 differentially expressed genes (DEGs) across the three groups (Fig. 1d, Supplementary Data 2, adj.p < 0.05). Analysis of the 2087 acinar signature genes revealed that the organoids lost most acinar lineage characteristics, which were mainly involved in normal acinar functions (Fig. S1f). On the other hand, the cultured organoids acquired only a portion of ductal genes including some ductal-specific transcription factors (Fig. S1g), highlighting the fact that they did not trans-differentiate into ductal lineage.

Recent mouse pancreas injury studies revealed that acinar cells could transform to multiple metaplastic populations during acinar-to-ductal metaplasia (ADM)^{15,16,17,18,19}. Tosti et al. showed the emergence of tuft cell and Mucin5B/ductal cell populations in human chronic pancreatitis samples²⁰. Many gene markers of these metaplastic populations were up-regulated in our acinar-derived organoids (such as AQP5, TFF2, MUC6, PGC, CLDN18, MUC5AC, TFF1, MUC5B, etc, Fig. 1e), suggesting that our 3D culture system mimics the in vivo pancreatic acinar injuries. To perform a gene expression comparison of our cultured acinar cells with referenced metaplastic cell populations, a pseudo-bulk RNA-seq data was created for each of these metaplastic populations by aggregating read counts from single cell RNA seq (scRNA-seq) data. The principal component analysis (PCA) showed that our cultured acinar organoids shared great similarities with chief-like cells, pit-like cells as well as Mucin5B/ductal cells identified in mouse and human pancreas disease models (Fig. 1f). Notably, the cellular origin of human pancreatitis associated Mucin5B/ductal cells was unclear, as lineage tracing is not possible in human clinical studies. However, the transcriptional similarity with our cultured organoids implies an acinar origin for this disease-associated cell type in human patients.

To investigate the potential heterogeneity of our cultured acinar cells, we performed a bulk RNA deconvolution analysis using a Multi-Subject Single Cell deconvolution (MuSiC) method²¹ to infer the cell type composition in our bulk RNA seq samples. By using a mice scRNA-seq dataset¹⁹ containing normal and metaplastic acinar cells as a reference, the deconvolution analysis inferred ~90% of our fresh acinar cells as normal acinar cells, demonstrating the robustness of the analysis (Fig. S1h). Importantly, the analysis inferred >90% of our cultured acinar cells as the metaplastic chief-like acinar cells, instead of any other cell types present in the reference dataset. The analysis thus showed a great possibility that our cultured acinar cells may resemble a specific metaplastic cell type with limited heterogeneity.

Cultured pancreatic exocrine cells maintained recognizable lineage-associated DNA methylation features

The substantial transcriptional and morphological changes made the lineage origin of cultured organoids ambiguous. We hypothesized that DNA methylation may remain relatively stable and can be used to verify lineage identity. To this end, reduced representation bisulfite sequencing was performed to assess the DNA methylation of fresh sorted acinar and ductal cells. The correlation of DNA methylation of all analyzed CpG sites was much higher among samples of a given lineage (Fig. 2a, S2a). Differentially hypermethylated sites were more likely to be found in introns and intergenic regions (Fig. S2b, c). Among the top expressed genes in the pancreas according to the Genotype-Tissue Expression (GTEx) project, promoters of genes associated with translation machinery were hypomethylated in the fresh cells of both lineages, while those associated with pancreatic digestive enzymes were hypomethylated in fresh acinar cells and hypermethylated in fresh ductal cells (Fig. 2b). A notable exception, the insulin (INS) gene was hypermethylated in both acinar and ductal cells. Consistent with RNA expression profile, most of the highly DEGs in fresh acinar cells were hypermethylated in fresh ductal cells and vice versa (Fig. S2d).

**Fig. 2: Verification of cultured cell identity by DNA methylation status.**

Although long-term 3D ductal organoid culture failed, we were able to establish four independent 2D ductal cultures from two donor tissues by introducing oncogenic KRAS and mutations in p16, TP53, and SMAD4 immediately after cell sorting. All the experiments throughout this work involving cultured or genetically modified ductal samples were all performed using 2D ductal culture. To validate the lineage authenticity of the established cultures, DNA methylation profiling was performed for five acinar 3D and four ductal 2D independent cultures. The hierarchy clustering analysis revealed that cultured acinar and cultured ductal cells were closely related with their fresh counterparts, respectively (Fig. 2a). In addition, although the gene expressions of pancreatic digestive enzymes were lost in cultured acinar organoids, the promoter methylation patterns for many of them were maintained (Figs. 2b, S2e).

Of the 5410 fresh acinar hypomethylated sites with a beta value difference of at least 0.8, 2691 (49.7%) were maintained, 1916 (35.4%) gained methylation in cultured acinar cells, and 803 (14.8%) lost methylation in cultured ductal cells (Fig. 2c). Of the 10735 fresh ductal hypomethylated sites, 5384 (50.1%) were maintained, 2894 (26.7%) gained methylation in cultured ductal cells, and 2457 (22.9%) lost methylation in cultured acinar cells (Fig. 2c). Gene Ontology analysis of the genes associated with these sites revealed that the maintained methylation patterns largely correlated with the normal functions of the cell of origin while altered DNA methylation patterns were associated with stress response. The genomic distribution of the sites within each methylation pattern was similar to the distribution of all hypomethylated sites in a given lineage, implying that changes in DNA methylation were not a result of generalized failure of DNA methylation maintenance enzymes (Fig. 2d, e). These data confirmed the lineage identity of our established cultures, which supported the conclusion that primary human acinar cells can be cultured in vitro as a model for studying pancreatic disease.

Human primary acinar and ductal cells can both form PDAC

Acquisition of oncogenic KRAS mutation is the earliest and the most prevalent genetic alteration in human PDAC²². To recapitulate the molecular events underlying PDAC initiation, we first overexpressed oncogenic KRAS^G12V in wild-type acinar organoids (referred to KRAS organoids) by lentiviral infection with a vector containing KRAS^G12V-mCherry. Surprisingly, the gain of oncogenic KRAS only led to the identification of two DEGs (fold-change >2; adj.p < 0.05) including KRAS and ST3GAL1, a known mediator of metabolic reprograming driven by oncogenic KRAS in mice PDAC²³ (Fig. 3a). Interestingly, we found that the unmodified wild-type acinar organoids exhibited elevated KRAS-induced PDAC transcription signatures identified in mouse models, such as glycolysis, steroid biosynthesis, and O-glycan biosynthesis pathways²³ (Fig. 3b). In addition, the wild-type acinar organoids expressed MUC5AC at a high level independently of oncogenic KRAS (Fig. S1d), while induction of MUC5AC expression in mouse ADM required oncogenic KRAS¹⁵. It is possible that supplements such as epidermal growth factor (EGF) in our culture medium may substitute for oncogenic KRAS to induce pre-cancer signatures in organoid culture. Nevertheless, these KRAS organoids failed to form tumors when transplanted into in NSG (NOD.Cg-Prkdc^scidIl2rg^tm1Wjl/SzJ) mice subcutaneously.

**Fig. 3: Genetically engineering human primary acinar and ductal cells to form PDAC.**

We next knocked out p16/CDLN2A (P), TP53 (T) and SMAD4 (S) genes in acinar KRAS organoids using CRISPR/Cas9 system, and compared with ductal-KPTS 2D cultures (Figs. 3c, S3a, b). RNA-seq analysis of three independent acinar-KPTS 3D cultures and four ductal-KPTS 2D cultures identified of >4000 DEGs (adj.p value < 0.05, fold change >2) between KPTS cells derived from two lineages (Fig. S3c). Notably, by comparing with a lineage-specific mouse PDAC model¹², we identified a group of genes significantly highly expressed in both human acinar-KPTS cells and mouse acinar-derived tumors, including MUC5AC, TFF1, TFF2, CLDN18, and REG1A (Fig. 3d, Supplementary Data 3). Similarly, a group of genes were identified that are significantly highly expressed in both human ductal-KPTS cells and mouse ductal-derived tumors, including EREG, WNT7B, EDL3, GATA3 and KCNAB1 (Fig. 3d). In addition, by comparing the DEGs between two lineages at fresh state and at KPTS state, we identified a list of genes whose lineage-associated expression pattern was maintained even after genetic modifications (Fig. S3d, Supplementary Data 4). To assess the heterogeneity among our samples from different donors and culture states, PCA analysis was performed including the fresh, cultured, genetically modified acinar and ductal samples collected in this work. Result showed that the samples clustered according to their respective culture states, as opposed to different donor origins (Fig. 3e).

The lack of direct evidence for acinar transformation in human disease prompted us to transplant the acinar and ductal KPTS cultures subcutaneously into immunodeficient NSG mouse to assess their tumorigenicity. Results showed that tumors can be reproducibly generated from both lineages harboring oncogenic KPTS mutations (acinar, n = 15, ductal, n = 30, Fig. 3f). We noted that ductal-derived tumors were generally larger than acinar tumors. Histological analysis revealed that both the acinar and ductal-derived tumor tissues had duct-like structures with intraluminal papillae and prominent hyalinized or desmoplastic stroma, resembling early human PDAC morphology (Fig. 3f). In addition, typical pancreatic intraepithelial neoplasia (PanIN) lesions were commonly observed in acinar-derived tumor sections. Immunofluorescence staining with human-specific antibody STEM121 and mCherry (expressed on the same cassette as oncogenic KRAS) confirmed the human origin of the cancer lesions (Figs. 3g, S3e). All of the tumor tissues had high levels of MUC5AC expression (Fig. 3f), which have been reported to express in metaplastic and cancer cells. We also observed expression of KRT19 and pERK in the tumors derived from both lineages (Fig. 3g). With these observations, we unambiguously demonstrated that both human acinar and ductal lineages are capable of transforming into malignant cells with a very similar phenotype. The striking similarities in histology and the expression of immunohistochemical markers between acinar- and ductal-derived tumors help us to understand why it is of great difficulty to identify the cellular origin of human PDAC in clinical samples.

Transcriptional reprograming in acinar- and ductal-KPTS cells

A recent scRNA-seq analysis identified several cell populations from human PDAC samples, including acinar, duct-like, PanIN, and PDAC cells with unique gene expression patterns²⁴. To compare our cells with the human PDAC samples, we examined the referenced cell type-specific gene expression in our RNA-seq data (Fig. 4a). Deconvolution analysis²¹ was performed to infer the cell type composition in our models using treatment naïve human PDAC scRNA-seq samples²⁴ as a reference. The analysis inferred >99% of our fresh acinar cells as normal acinar cells, and ~80% of our fresh ductal cells as ductal-like 1 cells present in the referenced human PDAC samples, confirming the robustness of such analysis (Fig. 4b). Consistent to our previous observation that cultured acinar organoids acquired disease-associated metaplastic features, ~85% of our cultured metaplastic acinar organoids were inferred as duct-like 2 cells which were categorized as a major source of malignant PDAC cells in the referenced study (Fig. 4b). Interesting, nearly 100% of our acinar-KPTS cells were inferred as PDAC cell population present in the referenced treatment naive human PDAC cases, while our ductal-KPTS samples were inferred to contain a small fraction of PanIN and duct-like 1 cells (Fig. 4b). The similarity of our KPTS cells to the treatment naive human PDAC cells confirmed the clinical relevance of our model system.

**Fig. 4: Transcriptomic reprograming in oncogenic cells derived from acinar and ductal lineages.**

To understand the early oncogenic reprograming in each lineage, we compared the acinar-KPTS cells to metaplastic acinar cells, and compared the ductal-KPTS cells to fresh ductal cells (Fig. S4a–c, Supplementary Data 5). Gene set overrepresentation analysis of the DEGs in KPTS cells of each lineage revealed diverse transcriptional changes in oncogenic cells, including common and lineage-specific changes (Fig. 4c, d). For example, cell cycle related gene sets were enriched in KPTS high genes from both lineages, indicating a common enhanced proliferation potential in oncogenic cells (Fig. 4c). KPTS cells from both lineages also shared enhanced expression of HALLMARK E2F target genes (Fig. 4e). Interestingly, gene sets related to telomere maintenance were only enriched in acinar-KPTS high genes, but not in ductal-KPTS high genes (Fig. 4c). A close look at the REACTOME extension of telomeres gene set revealed that many genes involved in the program, including TERT, were induced in acinar-KPTS cells, but not in ductal-KPTS cells (Fig. 4f). Other gene sets enriched in the KPTS high genes of both lineages include epithelial-mesenchymal transition (EMT), extracellular matrix organization, and RHO GTPase activate formins (Fig. S4d–f). The gene expression patterns across all the cell states revealed a dynamic transition from normal exocrine cells to an oncogenic cell state in response to environmental and genetic cues.

Intrinsic alterations in immune signaling in acinar- and ductal-KPTS cells

The gene set analysis of DEGs revealed a downregulation of immune-related pathways in acinar-KPTS cells (Fig. 4d). A comprehensive comparison of genes involved in antigen processing and presentation revealed different expression patterns in the genes involved in different parts of the antigen presentation process (Fig. 5a). A group of Rab GTPases involved in endocytosis of extracellular antigens were induced in both lineages after culture (Fig. 5a, b). Genes encoding the Cathepsin family of proteases in the lysosome were only induced in cultured acinar cells but not ductal cells. In addition, gene expression of B2M and TAP1/2, the key components in the MHC I pathway, were also downregulated in acinar-KPTS cells (Fig. 5a, b). Interestingly, genes encoding several MHC-I molecules as well as PD-L1 (CD274) were found to downregulate in KPTS cells from acinar or both lineages (Fig. 5c). Consistently, by using an antibody of human HLA-A, B, C molecules, we confirmed the reduced MHC I expression in acinar-KPTS cells compared to paired metaplastic acinar organoids using flow cytometry analysis (Fig. 5d). Dynamic change of antigen presentation pathway without immune pressure suggests a possible intrinsic mechanism of immune regulation in epithelial cells during early PDAC tumorigenesis.

**Fig. 5: Intrinsic alteration of immune program in oncogenic acinar and ductal cells.**

We also noted a general downregulation of genes involved in the complement cascade in both acinar and ductal-KPTS cells, including C3, C4, C1R, and C1S (Fig. 5e). However, the coagulation genes were upregulated in both acinar and ductal KPTS cells, which corroborates a previous finding that mice bearing pancreatic tumors have larger venous clots²⁵. These intrinsic changes observed in early PDAC-like cells may shed light on the currently less understood implication of the coagulation and complement systems in pancreatic cancer tumorigenesis. Other altered pathways in the KPTS cells included enhanced glycolysis in acinar-KPTS cells and alterations in p38MAPK cascade, O-linked glycosylation, and TNFα signaling via NFkb in the KPTS cells from both lineages (Fig. S5a–d). Overall, the analysis of common and lineage-specific transcriptional changes in KPTS cells revealed a proliferation-favored oncogenic phenotype with metabolic rewiring, ECM remodeling, EMT, and immune-evasion potential, resembling common cancer biology.

Analysis of early human PDAC models identifies potential diagnostic biomarkers

As current translational studies in human PDAC have mainly focused on cancer cell lines and patient derived tumor samples, we took advantage of our unique early PDAC model to identify early diagnostic markers. To this end, we first identified 140 genes which were significantly upregulated in acinar-KPTS organoids when compared with normal and metaplastic cells (fold change >4, adj.p < 0.05) (Fig. 6a, Supplementary Data 6). Similarly, 696 genes were identified which were significantly upregulated in ductal-KPTS cells (Fig. 6b, Supplementary Data 6). We then curated 2802 genes which were significantly highly expressed in TCGA PDAC samples compared with the GTEx normal pancreas dataset (fold change >4, adj. p < 0.05). Comparison of all the three groups of genes identified 51 overlapped genes, including 26 genes encoding extracellular and membrane proteins, which hold potential as candidates for early diagnostic markers (Fig. 6c, d). It has been demonstrated that TCGA PDAC samples have substantial amount of stromal and immune composition²⁶. Therefore, integration of our data from epithelial cells with the TCGA/GTEx comparison could help to minimize interference from mixed cell composition, while keeping the observation clinically relevant. Interestingly, among the 51 genes, AREG²⁷, DKK1²⁸, EREG²⁹, NT5E³⁰, ZBED2³¹, FAM83A³², and S100A2³³ are associated with PDAC prognosis and have been reported to play important roles in PDAC development. On the other hand, 27 of the 51 genes identified here either have not been associated with PDAC before or have unclear implications in PDAC development (e.g., AHNAK2, SNCG, WNT10A), thereby warranting further investigation.

**Fig. 6: Lineage-specific early PDAC model reveals candidates for diagnostic markers.**

To validate the clinical relevance of identified potential biomarkers (Fig. 6e), we first performed immunohistochemistry (IHC) staining of selected genes on our KPTS tumors and a human pancreatic cystic neoplasm as well as its adjacent normal tissue. Results showed that, all the tested proteins (AHNAK2, AREG, SEMA3A, SNCG and WNT10A) are highly expressed in our KPTS tumors originated from both lineages, as well as in the human pancreatic cystic tumor, but not in adjacent normal tissue (Figs. 6f, g, S6a). A more comprehensive validation was conducted by performing IHC staining on a human PDAC tissue array³⁴ containing paired tumor and adjacent normal area from 28 patients (Fig. 6h, i). Consistently, AHNAK2, a protein which was previously proposed as a PDAC prognosis marker with unknown function^35,36, was positive in tumor area of 25/28 patients, compared with only 1/28 patients positive at adjacent normal area (X-squared = 37.979, degree of freedom = 1, p value = 7.1 × 10⁻¹⁰). AREG, a member in EGF signaling which negatively correlates with PDAC prognosis³⁷, was positive in tumor area of 18/28 patients, compared with 9/28 patients positive at adjacent normal area (X-squared = 4.5773, degree of freedom = 1, p value = 0.0324). Taken together, these data confirmed the high expression profile of tested genes in both our early PDAC-like cells as well as advanced clinical PDAC samples, demonstrating their potential as biomarkers for PDAC early detection, possibly when used as a gene panel.

In addition to the 51 genes commonly found in all the three groups of genes, we also examined the 36 genes highly expressed in acinar-KPTS and TCGA PDAC samples, as well as 282 genes highly expressed in ductal-KPTS and TCGA PDAC samples (Fig. S6b). This led to identification of additional genes which may have lineage-specific implications in PDAC development.

Discussion

Although the acinar origin of PDAC has been demonstrated in mouse models^{8,9,10,11,12,13}, determining the cellular origin of human PDAC has remained a conundrum. This is largely due to the difficulty of long-term culturing acinar cells, and the lack of a reliable method to verify cell lineage because of the rapid and profound alterations to transcription these cells undergo when stressed. While previous reports have considered their cultured pancreatic organoids to be ductal origin^7,38, these studies determined ductal identity by examining the expression of specific acinar and ductal markers, which we demonstrated could also be rapidly altered in cultured acinar cells. In comparison, here we sorted two lineages and verified lineage identity through comprehensive DNA methylation profiling, providing more authentic lineage-specific information. We observed that DNA methylation patterns were largely maintained in cultured human exocrine pancreatic cells, and could be used to ascertain the cell of origin. Consequently, we can conclude that previous organoid culture conditions support acinar lineage growth and we successfully generated organoids with long-term proliferation capacity from sorted primary human pancreatic acinar cells³⁹. Genetically engineered acinar and ductal cells harboring four classic PDAC driver mutations were both capable of generating tumors in vivo. Therefore, we confidently conclude that human acinar and ductal cells can both develop into PDAC. It is of great interest to further investigate the degree to which the lineage specific methylation signatures are maintained in human PDACs.

We found that although cultured acinar organoids lost their most obvious lineage features and partially acquired ductal-like characteristics, they did not transdifferentiate into ductal cells. Instead, the acinar-derived organoids entered a unique state distinct from both normal acinar and ductal lineages. RNA expression of TFFs, mucins, as well as tuft cell markers known to be expressed by disease-specific populations identified in human pancreatitis patients were significantly up-regulated in acinar-derived organoids²⁰. Our data provided experimental evidence to support the acinar cell origin of these disease-specific populations.

We noted that the wild-type acinar organoids, even without the presence of a KRAS mutation, already became metaplastic and acquired a disease-associated signature. This observation might be explained by the facts that the acinar cells are highly plastic and prone to phenotypic change under in vitro culture stress, and that the partial activation of oncogenic KRAS pathway can be induced from the supplementation of EGF in the growth media. This aligns with findings from mouse models where a proto-oncogenic transcriptional program is initiated by pancreatic injuries before the acquisition of KRAS mutations^16,17. Thus, introducing oncogenic KRAS to acinar culture did not cause significant phenotypic changes. We postulated that oncogenic KRAS in acinar cells may be an essential prerequisite, rather than a sole driver, for PDAC transformation in our model system.

Our model recapitulated the disease progression-associated transcriptional transition, highlighting the unique advantage of our culture model in investigating the mechanistic aspects of early human PDAC tumorigenesis. The proliferation potential showed a progressive enhancement from normal cells to early PDAC-like cells. The upregulation of coagulation genes in both acinar and ductal KPTS cells provides a possible mechanism for increased venous clots in PDAC mouse model. Further studies are needed to illustrate the roles of the coagulation and complement cascade in PDAC tumorigenesis. MHC molecules were down-regulated in KPTS organoids after acquiring p16, TP53 and SMAD4 mutations especially in acinar lineage. Recent studies reported that TP53 increases the expression of MHC molecules via ERAP1⁴⁰ and IRF2⁴¹, whose expression remained unchanged in our organoids, suggesting that MHC molecules were down-regulated by other mechanisms. In addition, the down-regulation of MHC molecules in KPTS organoids and PD-L1 in acinar lineage occurred in the absence of selective pressure from an active immune system, indicating the intrinsic effects of cell lineage and the oncogenic mutations on promoting immune escape in PDAC cells.

One of the major obstacles to improving human PDAC survival is the lack of early diagnostic methods. Current human PDAC studies mainly rely on cancer cell lines or clinical samples derived from PDAC patients who already have symptomatic disease, which are not suitable for identifying early diagnostic markers. In comparison, our engineered cells acquired both PanIN histology and a PDAC associated transcriptomic signature, suggesting an early PDAC-like state, which is in a unique position to investigate early tumorigenesis and identify early diagnostic markers. In the present study, we took advantage of our early PDAC model and identified a group of genes with elevated expression that align with early PDAC progression, which were also found to be highly expressed in TCGA PDAC samples compared with the GTEx normal pancreas dataset. Many of these genes encode extracellular and membrane proteins, which hold potential as PDAC diagnostic markers. Using clinical human PDAC samples, we validated the protein expression patterns of selected genes in tumor and adjacent normal area, including AHNAK2, AREG, SEMA3A, SNCG, and WNT10A. Particularly, AHNAK2 was previously proposed as a PDAC prognosis biomarker⁴², corroborating the robustness of our findings. Interestingly, many of the genes identified in this study have either not been previously associated with PDAC or have unclear implications in PDAC development, warranting further investigation.

One limitation of our study is that the acinar and ductal cultures were established in different settings, i.e., 3D organoids vs 2D monolayers. It had been previously reported that the stiffness of tumor environment is associated with cancer progression⁴³. The average stiffness of human pancreatic PDX tissues is 1000–2000 Pa (the Young’s modulus), with some specific areas reaching a stiffness of up to 20,000 Pa⁴³. In comparison, Matrigel, similar to the matrix used in this study for 3D cell culture, is much softer with a stiffness of only ~90 Pa. Indeed, De la Peña et al. revealed that different culture conditions resulted in differences in cell transcriptomic profile, interaction with stromal components, as well as drug response⁴³. Thus, the different features of acinar- and ductal-KPTS cells and tumors could be attributed to the different stiffness in 3D vs 2D culture environment. On the other hand, the fact that acinar cells can be established as 3D organoids and ductal cells can only be established in 2D culture with PDAC-mutations suggests a difference in stiffness requirements of each lineage during PDAC initiation. In addition, we observed elevated TERT expression in acinar lineage but not in ductal lineage, which may contribute to limited growth of ductal cells. Using lineage tracing of endogenous Tert locus, Neuhöfer et al., have identified a rare TERT-positive subpopulation of pancreatic acinar cells dispersed throughout the mouse exocrine compartment⁴⁴. The higher expression of TERT in our acinar metaplastic cells could be upregulation of TERT or expansion of existing TERT high cells, similarly to what was observed in the mouse model. Further study is required to understand the differences between acinar and ductal cells in tumorigenic capacity, interaction with tumor environment, and drug response.

Considering the current lack of an early human PDAC model, engineering normal human primary pancreatic cells offers an opportunity to decipher the initiation and early progression of human PDAC. This is a crucial step toward the goal of developing prevention and early diagnosis strategies for improving outcomes of this disease. Even though we present this unique model for studying cancer initiation from human primary pancreatic cells, where obtaining the human tissues from the early stages of pancreatic cancer is nearly impossible, the question remains as to how well the in vitro disease model can recapitulate the malignant process in patients. It would be interesting to use single-cell RNA sequencing on cultured organoids and xenograft tumors to experimentally compare our model with clinical samples to further validate the clinical relevance. In addition, adding immune components with humanized mice in our model may provide a better tumor microenvironment, making it more relevant to clinical settings.

In conclusion, we provided comprehensive experimental evidence that both human pancreatic acinar and ductal cells are capable of transforming into PDAC. We reconstructed the exocrine cell transformation process and revealed a dynamic change of transcriptomic profiles from a normal cell state to the oncogenic state. We reported a list of genes which were highly expressed during early transformation and in clinical PDAC samples which may represent candidates for PDAC diagnostic tests. These observations provide additional insights into the lineage specific aspects of human PDAC pathogenesis, and may assist future endeavors in the improvement of disease diagnosis, prevention, and treatment.

Methods

Ethical statement

All experiments involving normal human primary pancreatic tissues from organ donors were reviewed by the institutional review board at UT Health San Antonio. The tissues were de-identified, with only information on sex, race, age, weight, height and cause of death. The IRB committee has agreed that the project does not require IRB approval because it is either: Not human research as defined by DHHS regulations at 45 CFR 46 and FDA regulations at 21 CFR 56; The project does not include non-routine intervention or interaction with a living individual for the primary purpose of obtaining data regarding the effect of the intervention or interaction, nor do the researchers obtain private, identifiable information about living individuals.

Human pancreatic cystic neoplasm sample was collected and prepared at UT Health at San Antonio with patient’s consent in accordance with the guidelines. Experiment involving this clinical human PDAC sample was approved by the institutional review board at UT Health San Antonio (IRB protocol #20230412NHR).

All animal experiments were approved by the Institutional Animal Care and Use Committees at UT Health San Antonio (protocol #20130023AR), and were performed in accordance with relevant guidelines and regulations.

Isolation of human pancreatic cells from organ donors using flow cytometry

Human islet-depleted cell fractions were obtained from organ donors deceased due to acute traumatic or anoxic death by Prodo Laboratories, Inc, and were shipped overnight to our laboratory (n = 21, see donor information in Supplementary Data 1). The flow sorting procedures were performed as previously described with some modifications¹⁴. Briefly, exocrine tissue cells were incubated with FITC-conjugated UEA-1 (0.25 μg/ml, Vector Laboratories, Newark, CA, FL-1061-5) for 10 min. at 4 °C and washed with PBS. After washing, the cells were digested with TrypLE^TM Express (Life Technologies, Grand Island, NY, 12605-028) for 5−8 min at 37 °C. Cells were collected by centrifugation and washed with FACS buffer (10 mM EGTA, 2% FBS in PBS). After washing, cells were stained with Pacific blue-conjugated anti-CLA (BioLegend, San Diego, CA, 321308) and anti-7AAD (BioLegend, San Diego, CA, 420404) for 15 min at 4 °C. Cell pellets were collected by centrifugation and washed with PBS after staining. The cells were sorted using a FACSAria^TM II (BD Biosciences, San Diego, CA) and collected in 100% FBS. After sorting, cells were washed with serum-free Advanced DMEM/F-12 media (Life Technologies, Grand Island, NY, 12634-010).

3D organoid culture of sorted acinar and ductal cells

Sorted primary human acinar and ductal cells were cultured as 3D organoids⁷ embedded in the Type 2 Cultrex RGF Basement Membrane Extract (BME, R&D Systems, Minneapolis, MN, 3533-010-02 P). Briefly, ~0.5 × 10⁶ freshly sorted cells were washed with PBS and centrifuged. The cell pellet was resuspended in 10 µL ice cold BME, and placed in the bottom of a pre-warmed 24 well plate. After solidification at 37 °C for 5–10 min, 500 µL of organoid growth media were added into each well. The organoid growth media was composed of serum free advanced DMEM/F-12 media (Life Technologies, Grand Island, NY, 12634-010) supplemented with Wnt3a conditioned medium (50%)⁴⁵, recombinant human R-Spondin 1 (500 ng/ml, R&D Systems, Minneapolis, MN, 4645-RS), Noggin (200 ng/ml, R&D Systems, Minneapolis, MN, 6057-NG), FGF10 (100 ng/ml, R&D Systems, Minneapolis, MN, 345-FG), EGF (50 ng/ml, R&D Systems, Minneapolis, MN, 236-EG), PGE II (1 nM, Fisher Scientific, Waltham, 22-961-0), A83-01 (0.5 µM, R&D Systems, Minneapolis, MN, 2939), Nicotinamide (10 mM, Thermo Fisher Scientific, Waltham, MA, 48-190-7100GM), Penicillin/Streptomycin (1 mM, Sigma-Aldrich, St. Louis, MO, P4333), HEPES (10 mM, Life Technologies, Grand Island, NY, 15630), GlutaMax^TM (1X, Life Technologies, Grand Island, NY, 35050). The growth media was refreshed every 3-4 days until cells reached confluency. For subculture, the organoids were collected and digested with TrypLE^TM Express (Thermo Fisher Scientific, 12605-028), followed by gentle pipetting to release cells from extracellular matrix. Finally, a small fraction of cells were embedded in fresh BME for culture.

2D monolayer culture of sorted ductal cells

As ductal cells could not survive in 3D culture for more than 3−4 passages, we established long term 2D ductal culture for further experiments. Briefly, the floor of a 24 well plate was coated with 100 µL of 5% BME in advanced DMEM/F-12 followed by incubation at 37 °C for 5−10 min. The BME solution was then removed and replaced with a suspension of ~0.5 × 10⁶ freshly sorted ductal cells in 500 µL of advanced DMEM/F-12 media supplemented with 5% serum. The media was refreshed every 3−4 days until cells reached confluency, at which point TrypLE^TM Express was used to digest the cells for passage or for further experiments.

Electron microscopy

Transmission Electron Microscopy (TEM) was performed at the UT Health San Antonio Electron Microscopy Laboratory. The basic processing steps were the same as previously described⁴⁶. The freshly sorted acinar and ductal cells were fixed with a solution containing 1% glutaraldehyde plus 4% paraformaldehyde for 30 min. Tissue was imbedded in resin, then cut into 90 nm slices, and placed on copper grids. Uranyl acetate was used to stain the grids for 30 s in the microwave, followed by 20 s of Reynolds’ lead. AMT (advanced microscopy methods) software was used to image samples at 80 kV using a JEOL 1230 electron microscope.

RNA-seq sample preparation

Cell pellets of freshly sorted and cultured cells were collected for total RNA extraction using Zymo Direct-zol RNA Miniprep Kit (Zymo Research, Irvine, CA, R2063) following manufacturer’s instructions. RNA quality was verified by 2100 Bioanalyzer (Agilent Technologies) and Qubit 4 Fluorometer (Thermo Fisher Scientific). Indexed cDNA libraries were prepared from high quality RNA samples using the Illumina® Stranded mRNA Prep Ligation kit (Illumina, San Diego, CA, 20040532) following manufacturer’s instructions. The cDNA libraries were then submitted to the Greehey Children’s Cancer Research Institute (GCCRI) Genome Sequencing Facility at UT Health San Antonio for high throughput sequencing analysis using Illumina HiSeq 3000 or NovaSeq 6000 System.

RNA-seq data analysis

Sequencing reads were aligned to reference genome GRCh38 using TopHat 2.1.1 and gene expression was quantified using HTSeq 0.11.1. Differential expression analysis of the read counts from aligned RNA seq data was performed using DESeq2 1.36.0 package in R software. A pre-filtering process was applied for each analysis to remove genes with low read count, i.e., only keep genes with >10 reads in at least half of the samples of at least one comparing group. For two-group comparison, the DEGs were defined as fold change >2, and Benjamin-Hochberg (BH) adjusted p-value < 0.05. For three-group comparison, the DEGs were identified using the LRT function from DESeq2 1.36.0 package, and defined as BH adjusted p value < 0.05. K Means cluster was performed using the Complexheatmap 2.13.2 package in R in order to identify gene clusters with certain expression pattern. Gene expression heatmaps were generated using TPM (transcript per million) or z-score of transformed/normalized read count as indicated in each figure. Overrepresentation analysis for lists of genes were performed using the clusterProfiler 4.4.4 package in R with default settings. Gene Set Enrichment Analysis (GSEA) for comparing two groups of expression dataset was performed using GSEA software downloaded from the BROAD Institute. A significant enrichment was considered with multiple-test adjusted p value < 0.05. For PCA analysis, all the bulk RNA-seq data generated from our work were normalized followed by PCA analysis using DESeq2 package.

Comparison of bulk RNA-seq data with reference scRNA-seq data

Raw read count and metadata of referenced scRNA-seq data were downloaded according to the authors’ instructions from corresponding references^15,19,20,24. For PCA analysis, a pseudo-bulk RNA-seq data was created for each cell population present in referenced scRNA-seq data by aggregating the read count of all the cells present in each population using Seurat 4.3.0.1 package in R software. Then all the pseudo-bulk RNA-seq data as well as the RNA-seq data generated from our work were normalized using DESeq2 1.36.0 package and corrected for batch effect using limma 3.52.4 package in R software, followed by PCA analysis using DESeq2. Deconvolution of our bulk RNA-seq data was performed using MuSiC 1.0.0 package in R software with previously characterized scRNA-seq data as references^19,24. When using human PDAC scRNA-seq samples as a reference, only treatment naïve human PDAC samples were included. For most accurate deconvolution analysis, the referenced scRNA-seq data was pre-processed in Seurat 4.3.0.1 and trimmed to only contain top DEGs in each cell type present in the dataset.

DNA methylation sequencing

Genomic DNA was extracted from pellets of freshly sorted and cultured pancreatic acinar and ductal cells using the Zymo Quick-DNA^TM MiniPrep kit (Zymo Research, Irvine, CA, D3024) as according to manufacturer instructions. DNA quality was verified by Qubit 4 Fluorometer (Thermo Fisher Scientific). Library preparation was performed on 500–1000 ng of genomic DNA using the TruSeq Methyl Capture EPIC Library Prep Kit (Illumina, San Diego, CA, FC-151-1003), with which bisulfite conversion and PCR amplification of regions of interest was performed. Sequencing of the resulting reduced-representation DNA methylation sequencing libraries was performed using an Illumina NovaSeq 6000 at the GCCRI Genome Sequencing Facility. Alignment of sequencing files to GRCh38 and CpG calling was performed using Bismark 0.19.1. For subsequent analysis, only CpG sites for which there were at least 10 aligned reads for all samples were used. Methylation at a CpG site was calculated as the number of methylated reads divided by the total number of reads at that site (β-value), and the methylation of a genomic region was calculated as the mean of the β-values of all sites within that region. Differential methylation between regions was calculated using two-tailed Student’s t test, with a region being considered differentially methylated if the FDR corrected p value was less than 0.05.

Organoid histology sample preparation

The cultured organoids were collected by pipetting, washed with PBS twice, and fixed in 10% formalin for 4 h. The organoids were washed with PBS again, then resuspended in 50 µl of pre-warmed 4% low-melting point agarose (48 °C). Then the cell suspension was quickly transferred onto a cold glass slide on ice, which was maintained on ice for an additional 5 min to allow solidification. The solid agarose was transferred to a tissue block cassette and kept in 70% ethanol for further paraffin block preparation and histological examination.

Genetic engineering of human primary pancreatic cells

A plasmid expressing oncogenic KRAS^G12V cDNA and mCherry was a generous gift from Seung Kim (Stanford University)³⁹. CRISPR guide RNAs for p16, TP53, and SMAD4 were designed and cloned into lentiCRISPR v2 plasmids (Addgene, Watertown, MA, #52961). Lentiviruses containing these expression constructs were packaged in 293 T cells by co-transfection with packaging plasmids pMD2.G (Addgene, Watertown, MA, #12259) and psPAX2 (Addgene, Watertown, MA, #12260). The sorted primary acinar and ductal cells were transduced with lentivirus with supplement of polybrene. The transduced cells were then subject to antibiotic and/or functional selections. For selection of KRAS^G12V transduction, G418 (1000 ug/mL) was added into organoid culture medium. For selection of CRISPR-p16 transduction, puromycin (1 µg/ml) was added into the culture medium. For selection of TP53 mutation, 10 µM nutlin-3 was added. For selection of SMAD4 mutation, Noggin-free media was used for cell culture, supplemented with 200 ng/mL BMP4. The expression of mCherry in the KRAS^G12V cassette was confirmed by RNA seq analysis. The mutations in p16, TP53, and SMAD4 were confirmed by Sanger sequencing.

Oligo DNA sequences:

p16 sgRNA: GGCTGGCCACGGCCGCGGCC

TP53 sgRNA: ACTTCCTGAAAACAACGTTC

SMAD4 sgRNA: TACGAACGAGTTGTATCACC

p16 mutation genotyping forward primer: CGGTCCCTCCAGAGGATTTG

p16 mutation genotyping reverse primer: TGGAGGCTAAGTAGTCCCAG

TP53 mutation genotyping forward primer: TGCTGGATCCCCACTTTTCC

TP53 mutation genotyping reverse primer: GGATACGGCCAGGCATTGAA

SMAD4 mutation genotyping forward primer: CTGAGCACAGGCCTTGAAATTA

SMAD4 mutation genotyping reverse primer: GTCGCGGGCTATCTTCCAAA

Flow cytometry analysis of MHC molecule expression

Paired wild type acinar organoids and acinar-KPTS cells were collected by TrypLE^TM Express digestion, and washed with PBS. After washing, cells were stained with FITC anti-human HLA-A,B,C antibody (BioLegend, San Diego, CA, 311403), FITC anti-human HLA-DR, DP, DQ antibody (BioLegend, San Diego, CA, 361705), and FITC Mouse IgG2a isotype control (BioLegend, San Diego, CA, 400209) for 30 min at 4 °C. Cell pellets were collected by centrifugation and washed with FACS buffer after staining, followed by flow cytometry analysis using a BD LSRII (BD Biosciences). Data was analyzed with Flowjo v10 software.

Animal experiments

All animal experiments were approved by the Institutional Animal Care and Use Committees at UT Health San Antonio (20130023AR), and were performed in accordance with relevant guidelines and regulations. The maximal tumor size in each mouse did not exceed 2 cm at the largest diameter as permitted by institutional guidelines. Four to six-week old female and male NSG (NOD.Cg-Prkdc^scidIl2rg^tm1Wjl/SzJ) mice (Strain #:005557) were purchased from The Jackson Laboratory. The mice were housed at a maximum of five per cage in a pathogen-free system with water and food ad libitum, with 12 h day/night cycle at 20–25 °C and 50–60% humidity. For subcutaneous transplantation, ~1 × 10⁶ cells were collected and suspended in 100 µL of 50% BME/50% serum-free Advanced DMEM/F-12 on ice. Tumor xenografts were established by subcutaneously injecting the cell mixture into the hind flank of NSG mice. The mice were maintained with a standard diet for 3 months to allow tumors to grow. At end point, the mice were euthanized, and the tumor tissues were collected for further histological analysis. The animal sex was not considered in the study design and analysis as no evidence for the impact of sex on the subcutaneous tumorigenesis of pancreatic cancer cells.

Immunofluorescence and IHC staining of tissue sections

Human pancreatic cystic neoplasm sample was collected from a 71-year old black male at UT Health at San Antonio with patient’s consent in accordance with the guidelines (IRB protocol #20230412NHR). Human PDAC tissue array contained tumors and adjacent normal area were previously generated from patients who underwent pancreatectomy at MD Anderson Cancer Center from 1990 to 2010³⁴. For Immunostaining, paraffin-embedded organoid/tissue block were deparaffinized, rehydrated, and submerged in 200 °C heated R-Universal Epitope Recovery Buffer solution (Electron Microscopy Sciences, Hatfield, PA, #AP0530) for 30 min and then let cool at room temperature for 25 min. Sections were permeabilized using 0.5% PBST (0.5% Triton X-100, Acros Organics, Fair Lawn, NJ) for 10 min. Sections were subsequently blocked with 5% donkey serum in 0.1% PBST for 35 min at room temperature. Sections were then incubated with primary antibodies diluted in 5% donkey serum in 0.1% PBST at 4 °C overnight. For immunofluorescent staining, sections were incubated with fluorescent-tagged Alexa Fluor secondary antibodies (1:250, Jackson ImmunoResearch, West Grove, PA) diluted in 5% donkey serum in 0.1% PBST for 1 h at room temperature. Additionally, sections were incubated with DAPI (1:1000, Invitrogen, Carlsbad, CA, P36935) for 4 min at room temperature. Finally, sections were covered with a drop of VectaShield Vibrance Antifade Mounting Medium (Vector Laboratories, Inc., Burlingame, CA, H-1700). For immunohistochemistry, following primary antibody incubation, sections were incubated with biotinylated secondary antibody diluted in 5% donkey serum in 0.1% PBST for 1 h at room temperature. Then, sections were incubated with Streptavidin-Horseradish Peroxidase Pre-diluted (1X, BD Pharmingen, San Diego, CA, 51-75477E) for 1 h at room temperature. The color-complex was developed using DAB Substrate Kit (BD Pharmingen, San Diego, CA, 550880). Finally, sections were dehydrated and covered with a drop of Poly-Mount (Polysciences, Inc., Warrington, PA, 08381-120). All images were captured using Leica DMI6000 B microscope and software (Leica Microsystems, Buffalo Grove, IL). All primary and secondary antibodies used are listed below:

Mouse anti human STEM121 (Takara Bio, #Y40410), dilution 1:50;

Mouse anti human/mouse/rat KRT19 (DSHB, #Troma-III), dilution 1:50;

Rabbit anti human Alpha-Amylase (Sigma Aldrich, #A8273), dilution 1:500;

Mouse anti human Mucin5AC (Santa Cruz Biotechnology, #sc-33667), dilution 1:50;

Rabbit anti human/mouse WNT10A (Thermo Fisher, #26238-1-AP), dilution 1:50;

Rabbit anti human AHNAK2 (Sigma Aldrich, #HPA002940), dilution 1:200;

Mouse anti human/mouse/rat AREG (Santa Cruz Biotechnology, #SC-74501), dilution 1:50;

Rabbit anti human/mouse/rat SEMA3A (Abcam, #AB199475), dilution 1:300;

Mouse anti human/mouse/rat SNCG (Santa Cruz Biotechnology, #SC-65979), dilution 1:50;

Alexa Fluor® 488-conjugated AffiniPure Donkey Anti-Mouse IgG (H + L) (Jackson ImmunoResearch, #715-545-150), dilution 1:250;

Cy™3-conjugated AffiniPure Donkey Anti-Rat IgG (H + L) (Jackson ImmunoResearch, #712-165-150), dilution 1:250;

Alexa Fluor® 647-conjugated AffiniPure Donkey Anti-Rabbit IgG (Jackson ImmunoResearch, #711-605-152), dilution 1:250;

Biotinylated-Goat Anti-Mouse Ig (Multiple Adsorption) (BD Biosciences, #550337), dilution 1:100.

Quantification and statistical analysis

All the bioinformatics and related statistical analyses were performed using the R packages described in corresponding method sections and figure legends. Mean fluorescence intensity of flow cytometry data was analyzed by two tailed Student’s t test. The sample size in each experiment was described in corresponding result sections, figure legends as well as in Supplementary Data 1.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The raw and processed high throughput sequencing data generated in this study have been deposited and made publicly available at Gene Expression Omnibus under accession numbers GSE223153 and GSE222990. Raw read counts and metadata of referenced scRNA-seq datasets used in this study are available for download according to the authors’ instructions from corresponding refs. ^15,19,20,24, including GSE172380, GSE141017, [http://singlecell.charite.de/cellbrowser/pancreas/], and HTAN Data Coordinating Center Data Portal under the HTAN WUSTL Atlas [https://data.humantumoratlas.org/], respectively. GTEx normal pancreas RNA expression data can be accessed from GTEx Portal [https://gtexportal.org/home/downloads/adult-gtex#bulk_tissue_expression]. TCGA pancreatic cancer RNA expression data are available at GDC data portal [https://portal.gdc.cancer.gov/projects/TCGA-PAAD]. Human reference genome GRCh38 is available at [https://hgdownload.soe.ucsc.edu/goldenPath/hg38/bigZips/].

References

Rahib, L., Wehner, M. R., Matrisian, L. M. & Nead, K. T. Estimated projection of US cancer incidence and death to 2040. JAMA Netw. Open 4, e214708 (2021).
Article PubMed PubMed Central Google Scholar
Hidalgo, M. et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology 15, 8–18 (2015).
Article PubMed Google Scholar
Pandiri, A. R. Overview of exocrine pancreatic pathobiology. Toxicol. Pathol. 42, 207–216 (2014).
Article CAS PubMed Google Scholar
Busnardo, A. C., DiDio, L. J., Tidrick, R. T. & Thomford, N. R. History of the pancreas. Am. J. Surg. 146, 539–550 (1983).
Article CAS PubMed Google Scholar
Mazur, P. K. & Siveke, J. T. Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology. Gut 61, 1488–1500 (2012).
Article PubMed Google Scholar
Miyabayashi, K. et al. Intraductal transplantation models of human pancreatic ductal adenocarcinoma reveal progressive transition of molecular subtypes. Cancer Discov. 10, 1566–1589 (2020).
Article CAS PubMed PubMed Central Google Scholar
Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324–338 (2015).
Article CAS PubMed Google Scholar
Kopp, J. L. et al. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 22, 737–750 (2012).
Article CAS PubMed PubMed Central Google Scholar
Habbe, N. et al. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc. Natl. Acad. Sci. 105, 18913–18918 (2008).
Article ADS CAS PubMed PubMed Central Google Scholar
Guerra, C. et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11, 291–302 (2007).
Article CAS PubMed Google Scholar
Ferreira, R. M. M. et al. Duct- and acinar-derived pancreatic ductal adenocarcinomas show distinct tumor progression and marker expression. Cell Rep. 21, 966–978 (2017).
Article CAS PubMed PubMed Central Google Scholar
Flowers, B. M. et al. Cell of origin influences pancreatic cancer subtype. Cancer Discov. 11, 660–677 (2021).
Article CAS PubMed PubMed Central Google Scholar
Lee, A. Y. L. et al. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma. Gut 68, 487–498 (2019).
Article CAS PubMed Google Scholar
Liu, J. et al. TGF-β1 promotes acinar to ductal metaplasia of human pancreatic acinar cells. Sci. Rep. 6, 30904 (2016).
Article ADS CAS PubMed PubMed Central Google Scholar
Ma, Z. et al. Single-cell transcriptomics reveals a conserved metaplasia program in pancreatic injury. Gastroenterology 162, 604–620.e20 (2022).
Article CAS PubMed Google Scholar
Li, Y. et al. Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer. Nat. Cancer 2, 49–65 (2021).
Article CAS PubMed Google Scholar
Alonso-Curbelo, D. et al. A gene–environment-induced epigenetic program initiates tumorigenesis. Nature 590, 642–648 (2021).
Article ADS CAS PubMed PubMed Central Google Scholar
Huang, Y.-H. et al. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev. 32, 915–928 (2018).
Article CAS PubMed PubMed Central Google Scholar
Schlesinger, Y. et al. Single-cell transcriptomes of pancreatic preinvasive lesions and cancer reveal acinar metaplastic cells’ heterogeneity. Nat. Commun. 11, 4516 (2020).
Article ADS CAS PubMed PubMed Central Google Scholar
Tosti, L. et al. Single-nucleus and in situ RNA–sequencing reveal cell topographies in the human pancreas. Gastroenterology 160, 1330–1344.e11 (2021).
Article CAS PubMed Google Scholar
Wang, X., Park, J., Susztak, K., Zhang, N. R. & Li, M. Bulk tissue cell type deconvolution with multi-subject single-cell expression reference. Nat. Commun. 10, 380 (2019).
Article ADS CAS PubMed PubMed Central Google Scholar
Morris, J. P., Wang, S. C. & Hebrok, M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat. Rev. Cancer 10, 683–695 (2010).
Article CAS PubMed PubMed Central Google Scholar
Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656–670 (2012).
Article CAS PubMed PubMed Central Google Scholar
Cui Zhou, D. et al. Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer. Nat. Genet. 54, 1390–1405 (2022).
Article CAS PubMed PubMed Central Google Scholar
Hisada, Y., Ay, C., Auriemma, A. C., Cooley, B. C. & Mackman, N. Human pancreatic tumors grown in mice release tissue factor-positive microvesicles that increase venous clot size. J. Thrombosis Haemost. 15, 2208–2217 (2017).
Article CAS Google Scholar
Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu & Cancer genome atlas research network. integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185–203.e13 (2017).
Article Google Scholar
Nagathihalli, N. S. et al. Novel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-α: impact on gastrointestinal cancers driven by secondary bile acids. Cancer Res. 74, 2062–2072 (2014).
Article CAS PubMed PubMed Central Google Scholar
Liu, D.-J. et al. The role of Dickkopf-1 as a potential prognostic marker in pancreatic ductal adenocarcinoma. Cell Cycle 16, 1622–1629 (2017).
Article ADS CAS PubMed PubMed Central Google Scholar
Zhu, Z. et al. Epiregulin is up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochem. Biophys. Res. Commun. 273, 1019–1024 (2000).
Article CAS PubMed Google Scholar
Faraoni, E. Y. et al. CD73-dependent adenosine signaling through Adora2b drives immunosuppression in ductal pancreatic cancer. Cancer Res. 83, 1111–1127 (2023).
Article CAS PubMed PubMed Central Google Scholar
Somerville, T. D. D. et al. ZBED2 is an antagonist of interferon regulatory factor 1 and modifies cell identity in pancreatic cancer. Proc. Natl. Acad. Sci. 117, 11471–11482 (2020).
Article ADS CAS PubMed PubMed Central Google Scholar
Parameswaran, N. et al. A FAM83A positive feed-back loop drives survival and tumorigenicity of pancreatic ductal adenocarcinomas. Sci. Rep. 9, 13396 (2019).
Article ADS PubMed PubMed Central Google Scholar
Ohuchida, K. et al. Over-expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis. J. Pathol. 213, 275–282 (2007).
Article CAS PubMed Google Scholar
Foo, W. C. et al. Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Hum. Pathol. 44, 1024–1030 (2013).
Article CAS PubMed Google Scholar
Klett, H. et al. Identification and validation of a diagnostic and prognostic multi-gene biomarker panel for pancreatic ductal adenocarcinoma. Front. Genet. 9, 108 (2018).
Article ADS PubMed PubMed Central Google Scholar
Lu, D., Wang, J., Shi, X., Yue, B. & Hao, J. AHNAK2 is a potential prognostic biomarker in patients with PDAC. Oncotarget 8, 31775–31784 (2017).
Article PubMed PubMed Central Google Scholar
Su, X. et al. miR-33a-3p regulates METTL3-mediated AREG stability and alters EMT to inhibit pancreatic cancer invasion and metastasis. Sci. Rep. 13, 13587 (2023).
Article ADS CAS PubMed PubMed Central Google Scholar
Varga, Á. et al. Human pancreatic ductal organoids with controlled polarity provide a novel ex vivo tool to study epithelial cell physiology. Cell. Mol. Life Sci. 80, 192 (2023).
Article CAS PubMed PubMed Central Google Scholar
Lee, J. et al. Reconstituting development of pancreatic intraepithelial neoplasia from primary human pancreas duct cells. Nat. Commun. 8, 14686 (2017).
Article ADS PubMed PubMed Central Google Scholar
Wang, B., Niu, D., Lai, L. & Ren, E. C. p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1. Nat. Commun. 4, 2359 (2013).
Article ADS PubMed Google Scholar
Kriegsman, B. A. et al. Frequent Loss of IRF2 in cancers leads to immune evasion through decreased MHC Class I antigen presentation and increased PD-L1 expression. J. Immunol. 203, 1999–2010 (2019).
Article CAS PubMed Google Scholar
Bhasin, M. K. et al. Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier. Oncotarget 7, 23263–23281 (2016).
Article PubMed PubMed Central Google Scholar
Osuna de la Peña, D. et al. Bioengineered 3D models of human pancreatic cancer recapitulate in vivo tumour biology. Nat. Commun. 12, 5623 (2021).
Article ADS PubMed PubMed Central Google Scholar
Neuhöfer, P. et al. Acinar cell clonal expansion in pancreas homeostasis and carcinogenesis. Nature 597, 715–719 (2021).
Article ADS PubMed PubMed Central Google Scholar
Mihara, E. et al. Active and water-soluble form of lipidated Wnt protein is maintained by a serum glycoprotein afamin/α-albumin. eLife Sci. 5, e11621 (2016).
Article Google Scholar
Green, J. A. et al. Whirlin, a cytoskeletal scaffolding protein, stabilizes the paranodal region and axonal cytoskeleton in myelinated axons. BMC Neurosci. 14, 96 (2013).
Article PubMed PubMed Central Google Scholar

Download references

Acknowledgements

This work is supported by the Cancer Prevention and Research Institute of Texas (R1219, P.W.), NIH/NCI (R21 CA218968, P.W., R01 CA237159, P.W.), NIDDK (R01DK110361, P.W.), and the William and Ella Owens Medical Research Foundation (P.W.). P.W. is a Cancer Prevention and Research Institute of Texas (CPRIT) scholar, and the P.W. group was supported by CPRIT. Michael Nipper was supported by a pre-doctoral fellowship through CPRIT Research Training Award RP 170345; J.L. was supported by a post-doctoral fellowship through CPRIT Research Training Award RP140105 and is currently supported by the American Cancer Society and Mays Cancer Center for the American Cancer Society Institutional Research Grant Early Access Pilot Award (IRG-21-147-01-IRG, P30CA054174). A.D. is supported by the Initiative to Maximize Student Development (IMSD) T32 training grant (T32 GM148752). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors acknowledge Dr. Seung Kim (Stanford University) for kindly providing KRAS construct. The authors thank Dr. Efsun Arda (NIH) and Dr. Zhijie Liu for their critical comments. The authors acknowledge Dr. Junichi Takagi for kindly providing engineered cell line that produced biologically active Wnt/afamin. Part of data was generated in the Flow Cytometry Shared Resource at UT Health San Antonio which is supported by the NCI grant from Mays Cancer Center (P30CA054174), the CPRIT grant (RP210126) and NIH grant (1S10OD030432-01A1). EM images were captured at UT Health San Antonio Electron Microscopy Laboratory. High throughput sequencing data described in this study was generated in the Genome Sequencing Facility/Mays Cancer Center Next-generation Sequencing Facility, which is supported by UT Health San Antonio, NIH-NCI P30 CA054174 (Cancer Center at UT Health San Antonio) and NIH Shared Instrument grant S10OD030311 (S10 grant to NovaSeq 6000 System), and CPRIT Core Facility Award (RP220662 to Y.C.). Human pancreatic tumor tissues were procured from the Mays Cancer Center Biorepository led by Dr. Robin Leach and assisted by Austen Lee. Part of the histology studies were assisted by the Histology and Immunohistochemistry Laboratory at UT Health San Antonio.

Author information

These authors contributed equally: Yi Xu, Michael H. Nipper.

Authors and Affiliations

Department of Cell Systems & Anatomy, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA
Yi Xu, Michael H. Nipper, Angel A. Dominguez, Naoki Akanuma, Kevin Lopez, Janice J. Deng, Destiny Arenas, Ava Sanchez, Lu-Zhe Sun, Jun Liu & Pei Wang
Greehey Children’s Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA
Zhenqing Ye, Siyuan Zheng & Yidong Chen
Department of Population Health Sciences, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA
Zhenqing Ye, Siyuan Zheng & Yidong Chen
Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA
Francis E. Sharkey
Division of Surgical Oncology and Endocrine Surgery, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA
Colin M. Court
Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, 15213, USA
Aatur D. Singhi
Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
Huamin Wang
Schulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, Rochester, MN, 55905, USA
Martin E. Fernandez-Zapico

Authors

Yi Xu
View author publications
You can also search for this author in PubMed Google Scholar
Michael H. Nipper
View author publications
You can also search for this author in PubMed Google Scholar
Angel A. Dominguez
View author publications
You can also search for this author in PubMed Google Scholar
Zhenqing Ye
View author publications
You can also search for this author in PubMed Google Scholar
Naoki Akanuma
View author publications
You can also search for this author in PubMed Google Scholar
Kevin Lopez
View author publications
You can also search for this author in PubMed Google Scholar
Janice J. Deng
View author publications
You can also search for this author in PubMed Google Scholar
Destiny Arenas
View author publications
You can also search for this author in PubMed Google Scholar
Ava Sanchez
View author publications
You can also search for this author in PubMed Google Scholar
Francis E. Sharkey
View author publications
You can also search for this author in PubMed Google Scholar
Colin M. Court
View author publications
You can also search for this author in PubMed Google Scholar
Aatur D. Singhi
View author publications
You can also search for this author in PubMed Google Scholar
Huamin Wang
View author publications
You can also search for this author in PubMed Google Scholar
Martin E. Fernandez-Zapico
View author publications
You can also search for this author in PubMed Google Scholar
Lu-Zhe Sun
View author publications
You can also search for this author in PubMed Google Scholar
Siyuan Zheng
View author publications
You can also search for this author in PubMed Google Scholar
Yidong Chen
View author publications
You can also search for this author in PubMed Google Scholar
Jun Liu
View author publications
You can also search for this author in PubMed Google Scholar
Pei Wang
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: P.W., J.L. Data curation: J.L., Y.X., M.H.N, A.A.D., N.A., K.L., J.J.D., D.A., A.S., P.W. Formal analysis: P.W., J.L., Y.X., M.H.N., A.A.D., N.A., K.L., Z.Y., Y.C., L.-Z.S., S.Z., A.D.S., F.E.S., H.W., M.E.F-Z. Funding acquisition: P.W. Methodology: J.L., Y.X., M.H.N., N.A., K.L. Project administration: P.W. and J.L. Supervision: P.W. Writing – original draft: J.L., Y.X., M.H.N., P.W. Writing – review & editing: J.L., Y.X., M.H.N., K.L., P.W., N.A., C.C.M., Z.Y., Y.C., L.S., S.Z., A.D.S., F.E.S., H.W.

Corresponding authors

Correspondence to Jun Liu or Pei Wang.

Ethics declarations

Competing interests

The authors declared no competing interests.

Peer review

Peer review information

Nature Communications thanks the anonymous reviewers for their contribution to the peer review of this work. A peer review file is available.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Peer Review File

Description of Additional Supplementary Files

Supplementary Data 1

Supplementary Data 2

Supplementary Data 3

Supplementary Data 4

Supplementary Data 5

Supplementary Data 6

Reporting Summary

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Xu, Y., Nipper, M.H., Dominguez, A.A. et al. Reconstitution of human PDAC using primary cells reveals oncogenic transcriptomic features at tumor onset. Nat Commun 15, 818 (2024). https://doi.org/10.1038/s41467-024-45097-2

Download citation

Received: 29 March 2023
Accepted: 15 January 2024
Published: 27 January 2024
DOI: https://doi.org/10.1038/s41467-024-45097-2

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.